SERA biotech catalysts & pipeline

SERA PROGNOSTICS INC · Data as of 2026-09-08

Upcoming catalysts

PreTRM® Test — NDA/BLA submission

Q3 2026

European expert commentary published supporting the role of biomarker-based risk prediction and biology-driven prevention strategies in addressing preterm birth, the convening of a European Expert Advisory Board representing nine countries, and completion of additional ELISA-based assay performance testing strengthened our CE marking submission package, with pre-application activities expected to commence in the third quarter and submission to conclude in the fourth quarter of 2026.

Source filing

PreTRM® Test — NDA/BLA submission

Q4 2026

European expert commentary published supporting the role of biomarker-based risk prediction and biology-driven prevention strategies in addressing preterm birth, the convening of a European Expert Advisory Board representing nine countries, and completion of additional ELISA-based assay performance testing strengthened our CE marking submission package, with pre-application activities expected to commence in the third quarter and submission to conclude in the fourth quarter of 2026.

Source filing

Explore the free biotech catalyst calendar